Last updated: March 1, 2026
What Is ORTHO-NOVUM 1/35-28?
ORTHO-NOVUM 1/35-28 is a combined oral contraceptive (COC) containing ethinyl estradiol (35 mcg) and norethindrone (1 mg). It is marketed globally, primarily in North America, Europe, and Asia.
Market Overview and Competitive Position
Market Size and Growth
The global oral contraceptives market was valued at approximately USD 7.5 billion in 2021 and expected to grow at a compound annual growth rate (CAGR) of 4.5% through 2028. The segment for combined oral contraceptives accounts for roughly 70% of this market.
Competitive Landscape
Key competitors include:
- Yasmin/Yaz (Bayer)
- Mirena (Bayer)
- Apri (Sii Medical)
- Lo Loestrin (Moss-Rosenstein)
ORTHO-NOVUM 1/35-28 remains a widely prescribed option, especially in regions where generics dominate. Its patent expiration in multiple jurisdictions suggests significant generic competition.
Patent and Regulatory Status
The original product was developed by Johnson & Johnson’s Ortho-Medical for Women division. The patent expired in the U.S. in 2004, enabling generics to enter the market. Current regulatory status varies per country:
- Approved in the U.S. and EU.
- Generic versions available since early 2000s.
- Market approval in Asia with varying sales volumes.
Financial and Commercial Fundamentals
Revenue and Market Share
The brand historically generated sales of US$250 million annually in key markets, with a declining trend due to patent expiry and generics.
Pricing and Reimbursement Dynamics
Pricing varies:
- U.S.: Average retail price approximately USD 30–40 per cycle.
- Europe: Varies based on healthcare policies. Reimbursement often available under national health services.
Pricing pressure due to generics has reduced margins, impacting revenue stability.
Distribution and Supply Chain
Manufactured primarily in North America and Europe. Distribution channels include pharmacies, clinics, and hospitals. Supply chain vulnerabilities include raw material shortages for hormone synthesis and manufacturing constraints during COVID-19.
Investment Considerations
Opportunities
- Potential for niche marketing targeting specific populations, such as women seeking non-hormonal or low-dose options.
- Increasing acceptance of oral contraceptives in emerging markets.
- Potential reformulations or combination variants.
Risks
- Patent expiration leading to generic competition.
- Pricing reductions driven by market saturation.
- Regulatory changes impacting approval or reimbursement.
- Declining sales due to shifts toward long-acting reversible contraceptives (LARCs).
Regulatory and Patent Landscape
No current patents protect ORTHO-NOVUM 1/35-28 post-2004 in the U.S., increasing vulnerability to generic competition. Patent status in other markets varies but is generally expired or not enforced.
R&D and Pipeline Developments
Minimal recent R&D activity; product largely mature. Future growth dependent on new delivery systems, such as transdermal or injectable contraception, or focusing on hormonal alternatives.
Strategic Recommendations
- Focus on markets with limited generic penetration.
- Explore partnership opportunities for reformulation or combination products.
- Invest in marketing targeted at demographic shifts favoring oral contraceptives.
- Monitor regulatory policies affecting reproductive health products.
Key Market Trends
- Rising demand in emerging economies.
- Growing preference for combination pills to reduce pill burden.
- Shift toward minimal hormone doses for safety and tolerability.
Key Takeaways
- ORTHO-NOVUM 1/35-28 is a mature product facing generic competition and pricing pressures.
- Growth prospects depend on market segmentation, regional regulations, and strategic repositioning.
- The overall oral contraceptive market remains resilient but is becoming more commoditized.
- Innovation, such as new formulations, may be necessary to sustain market relevance.
- Declining patent protection dictates a focus on niche marketing and product differentiation.
FAQs
1. What is the primary revenue driver for ORTHO-NOVUM 1/35-28?
Sales volume within regions with limited generic competition, mainly through prescription renewals and long-term contraceptive plans.
2. How does patent expiry affect market competition?
Patent expiry in the U.S. in 2004 allowed generics to enter freely, significantly reducing brand market share and pricing power.
3. Are there regulatory barriers for new formulations?
Yes, approval processes vary per jurisdiction, with strict safety and efficacy requirements for any reformulation or new delivery system.
4. What are the main competitors to ORTHO-NOVUM 1/35-28?
Generic oral contraceptives, including combinations like Loestrin and Yaz, account for significant market share.
5. How should investment risks be managed?
Focus on regions with patient brand loyalty, consider partnership options for product innovation, and monitor regulatory changes affecting contraceptive approvals.
References
[1] MarketsandMarkets. (2022). Oral Contraceptives Market by Type, Application, and Region - Global Forecast to 2028.
[2] IQVIA. (2022). Global Reproductive Health Market Insights.
[3] U.S. Food and Drug Administration. (2022). Patent and exclusivity information for oral contraceptives.
[4] European Medicines Agency. (2022). Market authorizations for contraceptive products.
